Contract awarded for plague vaccine

DynPort Vaccine Co. was recently awarded a $987,888 contract to perform plague vaccine work for the United Kingdom’s Ministry of Defense.

Company officials told that they will work with the London office of ERA Consulting to work on licensure of the plague vaccine.

The vaccine is designed to provide protection against the plague bacterium Yersinia pestis. The vaccine, which is currently going through Phase 2 clinical trials, will be in an aerosolized form.

DynPort President Robert V. House told the that his company has made great strides in advancing the plague vaccine toward licensure.

“This contract will build upon that work, laying a solid foundation for licensure of this important medical countermeasure in Europe,” House told “This work is also an important milestone for DVC, expanding our work beyond U.S. biodefense and into the global arena.”

House said that researchers with the U.S. Army Medical Research Institute of Infectious Diseases originally identified and developed the vaccine. Since that time, the development of the vaccine has become a collaborative effort by the defense departments of the United States, Canada and the United Kingdom for the mutual protection of allied military personnel.

The vaccine has not yet been licensed by the FDA or other regulatory bodies, House said, reports.